Skip to main content
. 2019 May 16;4(10):e125052. doi: 10.1172/jci.insight.125052

Figure 3. scAAV vector harboring artificial Plp1-miRNA effectively suppressed Plp1 mRNA and protein expression.

Figure 3

Coronal sections of P14 WT mice brains with Plp1 immunostaining in the CC (A–D), CS (E–H), and IC (I–L). The Plp1 expression in Venus-positive areas are detected in WT mice treated with scAAV.CNP.Venus.miRneg (A, B, E, F, I, and J) and scAAV.CNP.Venus.Plp1miRNA (C, D, G, H, K, and L). Images are representative of 5 mice per group. Scale bar: 50 μm. (M) Quantification of the Plp1 fluorescence intensities in scAAV-infected areas relative to corresponding AAV-uninfected areas in the contralateral hemisphere (n = 5 mice per group, 3 sections per site in each mouse). (N) Plp1 mRNA expression in Venus-positive oligodendrocytes from mice treated with scAAV.CNP.Venus.miRneg or scAAV.CNP.Venus.Plp1miRNA isolated by fluorescence-activated cell sorting. Mean relative expression of Plp1 mRNA in the scAAV.CNP.Venus.miRneg-treated group was set to 1 (n = 4 samples per group; in each sample, Venus-positive cells from 3 mice were pooled). Statistical significance was determined using 2-tailed Student’s t test. *P < 0.05; **P < 0.01.